Selected article for: "clinical management and inflammatory response"
Author: Soni, Vivek Kumar; Mehta, Arundhati; Ratre, Yashwant Kumar; Tiwari, Atul Kumar; Amit, Ajay; Singh, Rajat Pratap; Sonkar, Subash Chandra; Chaturvedi, Navaneet; Shukla, Dhananjay; Vishvakarma, Naveen Kumar
Title: Curcumin, a traditional spice component, can hold the promise against COVID-19?
  • Cord-id: l9cns9fh
  • Document date: 2020_11_5
    • ID: l9cns9fh
    Snippet: The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Curcumin, known for its pharmacological abilities especially as an anti-inflammatory agent, can be hypothesized as a potential candidate in the therapeutic regimen. COVID-19 has an assorted range of pathophysiological consequences,
    Document: The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Curcumin, known for its pharmacological abilities especially as an anti-inflammatory agent, can be hypothesized as a potential candidate in the therapeutic regimen. COVID-19 has an assorted range of pathophysiological consequences, including pulmonary damage, elevated inflammatory response, coagulopathy, and multi-organ damage. This review summarizes the several evidences for the pharmacological benefits of curcumin in COVID-19-associated clinical manifestations. Curcumin can be appraised to hinder cellular entry, replication of SARS-CoV-2, and to prevent and repair COVID-19-associated damage of pneumocytes, renal cells, cardiomyocytes, hematopoietic stem cells, etc. The modulation and protective effect of curcumin on cytokine storm-related disorders are also discussed. Collectively, this review provides grounds for its clinical evaluation in the therapeutic management of SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • ace1 expression and acute lung injury: 1
    • ace1 expression and acute respiratory: 1, 2
    • ace1 expression and acute respiratory sars syndrome: 1, 2
    • acid production and acute ards respiratory distress syndrome: 1, 2
    • acid production and acute lung injury: 1, 2, 3, 4
    • acid production and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acid production and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6
    • activate protease and acute respiratory: 1, 2, 3, 4, 5
    • activate protease and acute respiratory sars syndrome: 1, 2, 3, 4
    • activator signal transducer and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • activator signal transducer and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activator signal transducer and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activator signal transducer and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute lung injury: 1, 2
    • active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25